Browsing: Hodgkin

Adults who survived at least 5 years after a diagnosis of Hodgkin lymphoma had a standardized mortality ratio (SMR) of…

Despite excellent cure rates in Hodgkin lymphoma (HL) [1], 10–15% of patients experience primary treatment failure or long-term treatment-associated complications…

At the 2026 European Hematology Association (EHA) Congress, long-term data from the phase 2 KEYFORM-008 trial (NCT05508867) were presented by…

PD-1 blockade has become a cornerstone of treatment for patients with relapsed or refractory classic Hodgkin lymphoma (cHL), yet most…

Pembrolizumab (Keytruda) plus cyclophosphamide, vincristine, prednisone, and dacarbazine for 28-day cycles (COPDAC-28) with or without radiotherapy demonstrated promising antitumor activity…

Favezelimab, a LAG-3 inhibitor, plus pembrolizumab (Keytruda) exhibited a significant progression-free survival (PFS) benefit and trended toward favorable overall survival…

A treatment regimen containing brentuximab vedotin (Adcetris), etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone (BrECADD) displayed favorable progression-free survival (PFS) outcomes…

Giving the PRMT5 inhibitor AZD3470 as monotherapy showed clinical activity among patients with classic Hodgkin lymphoma who relapsed or were…

Previously, treating stage III or IV classical Hodgkin lymphoma involved a difficult trade-off between curative efficacy and significant toxicity. The…

Early studies identifying a signal with PD-1 blockade in patients with advanced Hodgkin lymphoma being treated in the frontline setting…